Welcome to our dedicated page for APOLLOMICS news (Ticker: APLM), a resource for investors and traders seeking the latest updates and insights on APOLLOMICS stock.
Apollomics Inc. reports developments as a clinical-stage biopharmaceutical company focused on oncology drug candidates for difficult-to-treat and treatment-resistant cancers. Its recurring updates center on vebreltinib (APL-101), a selective c-Met inhibitor being developed for non-small cell lung cancer and other tumors with c-Met alterations, along with pipeline assets that include targeted therapies, immuno-oncology candidates and other novel oncology mechanisms.
Company news also covers financial results, financing actions, collaborations for development and commercialization, board and committee changes, auditor and listing-status matters, operational continuity, and litigation-related resolutions. These updates connect Apollomics' clinical programs with its cash resources, governance, public-market status and partner agreements.
Apollomics (Nasdaq: APLM) announced that on July 8, 2026, Nasdaq Listing Qualifications Staff notified the company it has regained compliance with the Market Value of Listed Securities (MVLS) requirement under Nasdaq Listing Rule 5550(b)(2) for continued listing on the Nasdaq Capital Market.
According to Apollomics, Nasdaq previously notified the company on June 18, 2026 that it was out of compliance for failing to maintain a minimum MVLS of $35 million over 30 consecutive business days. Staff has now determined Apollomics’ MVLS was at least $35 million for 10 consecutive business days from June 23 to July 7, 2026, and the listing matter is closed.
Summary not available.
Apollomics (Nasdaq: APLM) reported full-year 2025 results and clinical updates on April 27, 2026. Key corporate facts: cash and equivalents $3.3M at December 31, 2025; 2025 revenue $8.5M (up from $0 in 2024) largely from an upfront licensing payment; and net loss $10.9M for 2025.
Clinical progress centers on vebreltinib (APL-101): NMPA approvals in China for three indications, ongoing global Phase 2 SPARTA study (282+ enrolled) and planned U.S. IND submission for accelerated approval in H1 2027 for NSCLC with c-MET amplification, per the company.
Apollomics (Nasdaq: APLM) entered a $2.0 million unsecured convertible promissory note with CEO Hung-Wen (Howard) Chen on March 30, 2026 to provide working capital for clinical development and general operations.
The Note bears 0% interest and will automatically convert upon a subsequent equity financing of at least $10.0 million at a 20% discount to that financing's lowest per-share price. The independent Audit Committee and Board approved the related-party terms, with the CEO abstaining from the vote.
Apollomics (Nasdaq: APLM) reported first-half 2025 results for the period ended June 30, 2025.
Key figures: cash and equivalents $2.1M (Dec 31, 2024: $9.8M); the company projects cash to fund operations into third quarter 2026. R&D expenses were $4.6M (H1 2025) versus $16.9M (H1 2024). G&A expenses were $14.5M (H1 2025) versus $10.2M (H1 2024). Net loss narrowed to $12.5M or $11.37 per share, compared with a $35.2M loss or $37.53 per share in H1 2024.
Apollomics (Nasdaq: APLM) entered a settlement resolving Cayman Islands litigation with TWVC related to preferred‑share redemptions before its 2023 merger with Maxpro Capital Acquisition Corporation. The company agreed to pay US$5.0 million in cash in several installments over two years plus approximately US$879,757.78 in legal expenses.
TWVC will withdraw all claims and the parties are submitting the Settlement Agreement for court approval to conclude the proceedings. The original damages claimed by TWVC were approximately US$40 million, as disclosed in Apollomics' April 2025 Form 20‑F.
Apollomics (Nasdaq: APLM) announced board changes on November 16-17, 2025: Po-Jen Hsueh resigned from the board and his resignation was stated as not related to any disagreement with the company. The board appointed Dr. Ya-Chi (Claudia) Huang to fill the vacancy and named her to the Audit Committee and the Nominating and Corporate Governance Committee.
Following the change, the seven-member Board includes Hung-Wen (Howard) Chen (chair), Hong-Jung (Moses) Chen, Yi-Kuei Chen, Hsien-Shu Tsai, Yi-An Chu, Chen-Huan Jan, and Ya-Chi (Claudia) Huang, with five independent directors.
Dr. Huang’s background highlights biotechnology investment and R&D: she is Assistant Vice President at Maxpro Ventures (joined 2024), director at AngenMed Therapeutics, previously worked at Diamond Biofund (participated in Diamond’s 2023 Taiwan Stock Exchange IPO), and holds a Ph.D. in Microbiology from National Taiwan University.
Apollomics (Nasdaq: APLM) said Nasdaq notified the company on October 14, 2025 that the Listing Qualifications Staff determined Apollomics is in compliance with Nasdaq continued listing requirements.
As a result, Nasdaq cancelled the previously scheduled appeal hearing and Apollomics securities will remain listed and continue to trade on The Nasdaq Stock Market. The company had earlier filed an application to appeal a delisting notification and requested a hearing before a Nasdaq Hearings Panel.
Apollomics (Nasdaq: APLM) announced operational continuity after a leadership change and new funding, reversing prior wind-up plans.
The company said it received $4.1 million in PIPE funding on Sept 3, 2025, appointed a new board and management team, and intends to continue its global Phase 2 SPARTA program for APL-101 (vebreltinib), which has data from >280 patients. All CRO contracts are reported fully paid; the company has 12 employees and expects 15 by Oct 31, 2025. Apollomics also cites existing Chinese approvals for APL-101 in MET-amplified NSCLC and GBM via partners and intends to pursue broader regulatory filings.
Apollomics (NASDAQ: APLM) reported its full year 2024 financial results and clinical updates. The company secured a strategic collaboration with LaunXP for vebreltinib development, bringing in a $10 million upfront payment. Key clinical highlights include a 43% objective response rate in non-CNS MET fusion solid tumors and 30% response rate in high MET gene copy number patients.
Financial results show cash position of $9.8 million as of December 31, 2024, compared to $37.8 million in 2023. R&D expenses decreased to $24.6 million from $34.2 million, while administrative expenses reduced to $17.8 million from $20.6 million. Net loss for 2024 was $(53.9) million or $(52.80) per share, improved from $(172.6) million loss in 2023.
The company implemented strategic expense reductions and expects current cash, combined with the LaunXP payment, to fund operations into Q1 2026.